| [1] |
Siegel R,Desantis C,Jemal A. Colorectal cancer statistics, 2014[J]. CA: Cancer J Clin, 2014, 64(2): 104-117.
|
| [2] |
Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location[J]. Ann Intern Med, 1990, 113(10): 779-788.
|
| [3] |
Boise MK,Johansen JS,Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer[J]. Annals of Oncology, 2013, 24(10): 2554-2559.
|
| [4] |
Ramesh O,Rana D,Habibollah M, et al. Anatomical Distribution of Colorectal Carcinoma in Iran: A Retrospective 15-yr Study to Evaluate Rightward Shift[J].Asian Pacific J Cancer Prev,2012,13(1),279-282.
|
| [5] |
Cheng L,Eng C,Nieman LZ, et al. Trends in colo-rectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005[J]. Am J Clin Oncol, 2011, 34(6): 573-580.
|
| [6] |
Weiss JM,Pfau PR,O'Connor ES, et al. Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data[J]. J Clin Oncol: official journal of the American Society of Clinical Oncology, 2011, 29(33): 4401-4409.
|
| [7] |
Wu, X,Chen, VW,Martin J, et al. Sub-site-specific colorectal cancer incidence rates and stage distributions among Asians an d Pacific Islanders in the United States, 1995 to 1999[J]. Cancer Epidemiol. Biomarkers Prev, 2004, 13(7): 1215-1222.
|
| [8] |
Araki K,Furuya Y,Kobayashi M, et al. Comparison of mucosal microvasculature between the proximal and distal human colon[J]. J Electron Microsc (Tokyo), 1996, 45(3): 202-206.
|
| [9] |
Skinner SA,O'Brien PE. The microvascular structure of the normal colon in rats and humans[J]. J Surg Res, 1996, 61(2): 482-490.
|
| [10] |
Roncucci L,Modica S,Pedroni M,et al. Aberrant crypt foci in patients with colorectal cancer[J]. Br J cancer, 1998, 77(12): 2343-2348.
|
| [11] |
Roncucci L,Medline A,Bruce WR. Classification of aberrant crypt foci and microadenomas in human colon[J]. Cancer Epidemiol Biomarkers Prev, 1991, 1(1): 57-60.
|
| [12] |
Bara J,Nardelli J,Gadenne C, et al. Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas[J]. Br J cancer, 1984, 49(4): 495-501
|
| [13] |
Sun Y,O'Riordan MX. Regulation of bacterial pathogenesis by intestinal short-chain Fatty acids[J]. Adv Appl Microbiol, 2013, 85: 93-118.
|
| [14] |
Macfarlane GT,Gibson GR,Cummings JH. Comparison of fermentation reactions in different regions of the human colon[J]. J Appl Bacteriol, 1992, 72(1): 57-64.
|
| [15] |
Povey AC,Hall CN,Badawi AF, et al. Elevated levels of the pro-carcinogenic adduct, O(6)-methylguanine, in normal DNA from the cancer prone regions of the large bowel[J]. Gut, 2000, 47(3): 362-365.
|
| [16] |
Payne CM,Bernstein C,Dvorak K,et al. Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis[J]. Clin Exp Gastroenterol, 2008, 1: 19-47.
|
| [17] |
Lax S,Schauer G,Prein K, et al. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis[J]. Int J Cancer Journal international du cancer, 2012, 130(10): 2232-2239.
|
| [18] |
Worthley DL,Leggett BA. Colorectal cancer: molecular features and clinical opportunities[J]. Clin Biochem Rev, 2010, 31(2): 31-38.
|
| [19] |
Reichmann A,Levin B,Martin P. Human large-bowel cancer: correlation of clinical and histopathological features with banded chromosomes[J]. Int J Cancer, 1982, 29(6): 625-629.
|
| [20] |
Delattre O,Olschwang S,Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer[J]. Lancet, 1989, 2(8659): 353-356.
|
| [21] |
Rothberg PG,Spandorfer JM,Erisman MD, et al. Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma[J]. Br J Cancer, 1985, 52(4): 629-632.
|
| [22] |
Russo A,Bazan V,Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53mutation: influence of tumor site, type of mutation, and adjuvant treatment[J]. J Clin Oncol, 2005, 20, 23(30): 7518-7528.
|
| [23] |
Weisenberger DJ,Siegmund KD,Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer[J]. Nat Genet, 2006, 38(7): 787-793.
|
| [24] |
Nosho K,Irahara N,Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample[J]. PloS One, 2008, 3(11): e3698.
|
| [25] |
Roth AD,Delorenzi M,Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage Ⅱ/Ⅲ colon cancer[J]. J Natl Cancer Inst. 2012, 104(21): 1635-1646.
|
| [26] |
Barault L,Charon-Barra C,Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases[J]. Cancer Res, 2008, 68(20): 8541-8546.
|
| [27] |
Bae JM,Kim JH,Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location[J]. Br J Cancer, 2013, 109(4): 1004-1012.
|
| [28] |
Yokota T,Ura T,Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer[J]. Br J Cancer, 2011, 104(5): 856-862.
|
| [29] |
Hampel H,Frankel WL,Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5783-5788.
|
| [30] |
Hinojosa MW,Konyalian VR,Murrell ZA, et al. Outcomes of right and left colectomy at academic centers[J]. Am Surg, 2007, 73(10): 945-948.
|
| [31] |
Kwaan MR,Al-Refaie WB,Parsons HM, et al. Are right-sided colectomy out-comes different from left-sided colectomy outcomes?: study of pa-tients with colon cancer in the ACS NSQIP database[J]. JAMA Surg, 2013, 148(6): 504-510.
|
| [32] |
Meguid RA,Slidell MB,Wolfgang CL, et al. Is there a difference in survival between right-versus left-sided colon cancers[J]? Ann Surg Oncol, 2008, 15(9): 2388-2394.
|
| [33] |
Price TJ,Beeke C,Ullah S, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease[J]? Cancer, 2015, 121(6): 830-835.
|
| [34] |
Ishihara S,Nishikawa T,Tanaka T, et al. Prognostic impact of tumor location in stage IV colon cancer: a propensity score analysis in a multicenter study[J]. Int J Surg, 2014, 12(9): 925-930.
|
| [35] |
Modest DP,Jung A,Moosmann N, et al.The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial[J]. Int J Cancer, 2012, 131(4): 980-986.
|
| [36] |
Brule SY,Jonker DJ,Karapetis CS, et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): nCIC CTG CO.17. J Clin Oncol, 2013, 31, (suppl, abstr 3528). Epub 2013 ASCO annual Meeting.
|
| [37] |
von Einem JC,Heinemann V,von Weikersthal LF, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial[J]. J Cancer Res Clin Oncol, 2014, 140(9): 1607-1614.
|